MeiraGTx Reacquires Bota-vec Global Rights from J&J Following Phase III Setback, Targets 2027 Commercial Launch

As early as 2019, Johnson & Johnson reached a broad collaboration agreement with MeiraGTx, paying an upfront fee of $100 million to jointly develop gene therapies for inherited retinal diseases. By the end of 2023, Johnson & Johnson further increased its investment through an asset purchase agreement worth approximately $415 million, acquiring bota-vec from MeiraGTx.Global Development and Commercialization RightsAt the time, the industry believed that Johnson & Johnson would leverage its strong clinical advancement capabilities and global commercialization network to quickly bring this therapy to market.

Previously, the FDA had granted bota-vec Fast Track and Orphan Drug designations, while EU regulatory authorities had awarded it Priority Medicines (PRIME), Advanced Therapy Medicinal Product (ATMP), and Orphan Drug designations.

However, more than two years later, the situation reversed, and MeiraGTx reacquired the asset for a relatively "low" upfront payment of $25 million. This kind of operation, shifting from "buying at a high price" to "selling at a low price," is not uncommon in the recent pipeline optimization of multinational corporations (MNCs). As the macroeconomic environment changes, large pharmaceutical companies are increasingly inclined to divest rare disease pipelines that are high-risk or have controversial clinical data. For Johnson & Johnson, giving up bota-vec might be a risk-aversion decision based on the Phase III clinical data not meeting expectations; but for MeiraGTx, regaining this core asset with late-stage clinical data represents a "high-stakes gamble" in its transition to becoming a commercial-stage biotechnology company.

Retinitis Pigmentosa (RP) is a group of rare hereditary eye diseases that cause progressive vision loss. Among all types of RP, X-linked Retinitis Pigmentosa (XLRP) is one of the most severe and rapidly progressing subtypes, accounting for approximately 15% of all RP cases. Due to its X chromosome-linked inheritance, the disease predominantly affects males. Patients typically begin experiencing night blindness in childhood, followed by a gradual narrowing of the visual field (tunnel vision), and some may progress to complete blindness by their twenties or thirties.

At the molecular biology level, approximately 70% to 80% of XLRP is caused by mutations in the RPGR (Retinitis Pigmentosa GTPase Regulator) gene. The RPGR protein plays a crucial role in ciliary transport within photoreceptor cells (rods and cones). When this gene is mutated, protein transport inside the photoreceptor cells is disrupted, leading to gradual cell dysfunction and eventual cell death.

In the face of XLRP, current clinical management is mainly limited to symptomatic support, such as wearing light-shielding glasses, taking vitamin supplements, etc., but none of these methods can stop or reverse the natural progression of the disease.

It is against this backdrop that bota-vec emerged as a potential "one-time" curative gene therapy. Its core mechanism involves the use of an engineered adeno-associated virus (AAV) vector to deliver a normal copy of the RPGR gene into the subretinal space. Theoretically, successful transduction of surviving photoreceptor cells to express normal RPGR protein should restore cellular function. During the early stages of development, MeiraGTx optimized the codons for the highly unstable purine-rich sequence (ORF15) within the RPGR gene.An important part of its technical advantage.

MeiraGTx’s ability to reclaim the pipeline at a lower cost this time, as well as the greatest regulatory challenges it faces, are all rooted in the complex performance of bota-vec in the LUMEOS III clinical trial.

According to publicly disclosed information, LUMEOS is a global, randomized, controlled Phase III clinical trial designed to evaluate the efficacy and safety of bota-vec in treating patients with XLRP. Unfortunately, the study did not meet its primary endpoint: significant improvement at 52 weeks as measured by the Vision-Guided Mobility Assessment (VMA) test.

VMA Test (or similar maze tests) are commonly used as functional endpoints in ophthalmic gene therapy, requiring patients to navigate through a maze filled with obstacles under varying lighting conditions. Previously, Spark Therapeutics' Luxturna (the first approved gene therapy for inherited eye diseases) relied precisely on such maze tests.Functional visual assessment as one of the key efficacy evidencesIt has received FDA approval. Bota-vec's failure to achieve statistically significant success on this widely accepted primary endpoint by regulatory authorities undoubtedly casts a shadow over its regulatory prospects.

However, MeiraGTx emphasized that patients who received treatment in both eyes showed clinically significant improvements in multiple objective and patient-reported subjective vision measurements.

Among the results, measurements from Microperimetry showed significant improvement in retinal sensitivity across multiple metrics for the treatment group. Under low-light conditions, 45% of patients in the treatment group gained more than 10 letters on the eye chart, and 20% gained more than 15 letters. In ophthalmic clinical practice, a 15-letter improvement is typically considered to have substantial clinical transformation value. Additionally, 40% of patients in the treatment group demonstrated improvements in two or more different visual domains (e.g., mobility, dim light function, emotional health), compared to zero in the untreated control group.

MeiraGTx's decision to repurchase the assets at this time is based on its confidence in these endpoint data.

Besides the "ray of hope" in clinical data, another major confidence for MeiraGTx to take over and plan for commercial release by 2027 lies in its control over the CMC process.

Many gene therapy companies, after achieving success in clinical trials, face obstacles during the regulatory approval stage due to their inability to achieve stable, high-quality vector production at a commercial scale.

In its previous collaboration with Johnson & Johnson, MeiraGTx, as the commercial manufacturer of this product, has completed the Process Performance Qualification (PPQ) and has mastered all the CMC data sets required for submissions to global regulatory authorities.

This means,After taking over the assets, although MeiraGTx may need to carry out some process validation work, it does not have to start technology transfer and process scale-up verification from scratch. Moreover, it can quickly initiate the marketing application process based on existing clinical and CMC data.

The market for gene therapy in ophthalmology for rare diseases currently presents a situation with both opportunities and challenges. On one hand, the combination of demand and technology continuously generates hope. The eye, as a relatively closed system, requires an extremely small dose of viral vectors, which not only reduces production costs but also significantly minimizes the risk of systemic immune reactions, making ophthalmology an important frontier in gene therapy.

On the other hand, the reality of commercialization is extremely harsh. Since the approval of Luxturna (targeting RPE65 gene mutations) in 2017, the ophthalmic gene therapy market has not experienced an immediate explosive growth.

Rare diseases mean dispersed patients. Globally, finding eligible XLRP patients requires specialized ophthalmic diagnosis and precise genetic sequencing, while the popularization of high-quality genetic screening remains costly. Subretinal injection is a highly specialized microsurgery, and during the commercialization phase, top retinal surgeons need to be trained, limiting the rapid penetration of the drug.

Although there are currently no approved therapies in the XLRP field, companies such as Biogen and Beacon Therapeutics are advancing AAV gene therapies targeting the RPGR gene. Once the future market is activated, it is likely to quickly evolve into a brutal "winner-takes-all" competition, where first-mover advantage is critical. This also explains why MeiraGTx will submit its marketing application based on existing data as soon as possible to seize the time window.

There is no denying that the regulatory future of bota-vec remains uncertain. The absence of the primary endpoint looms like the Sword of Damocles, potentially shattering the 2027 commercialization forecast at any moment. However, functional improvements demonstrated by other endpoints, along with the advocacy of the XLRP patient community, provide regulators with sufficient ethical and scientific grounds to exercise "flexible approval."